ArticleBiochemistry and biophysics reports2026
Mammalian evolution and human mutation burden in Rab GTPases.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rab GTPases are essential regulators of membrane trafficking with known roles in neurodegeneration, cancer progression and metastasis. While individually, Rabs have been extensively studied in disease and phylogenetic contexts, the overall evolutionary and mutation patterns that influence Rab function, at a family level, remain underexplored. Hence, we performed a family-wide investigation of Rabs in mammalian evolution integrated with disease-related mutations in modern humans. In this study, we analysed 54 Rab proteins across 62 placental mammals using branch-site models, to assess the extent of their sequence evolution across the mammalian lineages. We then combined these findings with the mutation data in human Rabs from UniProt. We defined three domain-level metrics, namely, constraint score, damage tolerance and overall mutation burden, to evaluate how Rab proteins as a whole, and in each of their domains, tolerate variation at the population level in humans. Our results suggest that the Rabs evolving across a larger number of mammalian species tended to show greater accumulation of damaging mutations in humans, particularly within the Switch I domain. This region is critical to Rab function and appears to exhibit cross-species variation while accommodating mutations relevant to human disease. The integrated framework used to examine mammalian Rab evolution and disease-related variation in human Rabs, can also be applied to investigate other conserved protein families implicated in diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.